Intrinsic Value

Not Available for 6L8

There is not enough data to reliably calculate the intrinsic value for Pulse Biosciences Inc.

Do our valuations actually work? See backtest results .

Alternatives to 6L8

Fundamental Analysis

What Pulse Biosciences Does

Health Care

Pulse Biosciences develops medical technology that uses very short electrical pulses to destroy unwanted tissue without the heat and mechanical damage of traditional ablation tools. Its main product work centers on systems for treating skin conditions and other soft tissue targets, using a method the company calls nanosecond pulsed field ablation.

Headquarters
United States of America US
Employees
116
IPO date
May 18, 2016
Read the full company overview
View Company Overview
Financials

Balance Sheet

Efficiency

Wall St Price Targets

Shareholder Returns

Competitive Landscape

Recent Events

Latest Earnings Call

Q3 2026 · November 5, 2026

Pulse Biosciences completed Nano-Pulse AF enrollment ahead of schedule and is shifting toward pre-commercial readiness while advancing its clinical programs.

Open the earnings call
EPS
−$0.32
Expected
−$0.35
Surprise
+8.6%
Stock, next trading day
+0.4%
View Earnings Call

Pulse Biosciences insiders are buying within their usual range

Insider trading · Last trade on Sep 1, 2026

Sold $2.9m 1 insider
Bought $26.8m 3 insiders
Trades by date
Open insider trading

Past 12 months

Continue 6L8 Research

Decided on Pulse Biosciences? Get an email when 6L8 reaches the price you’d buy at. Free with an account.

Other Pulse Biosciences listings

Back to Top